Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1305398
                    [Title] => New breast cancer therapy yields better outcomes
                    [Summary] => 
One person is diagnosed with breast cancer somewhere in the world every 22 seconds and more than three people die of breast cancer every five minutes.

                    [DatePublished] => 2014-03-27 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 1243290
                    [Title] => New drug helps people with advanced HER2-positive breast cancer live longer
                    [Summary] => 
Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.

	 

                    [DatePublished] => 2013-10-10 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 791677
                    [Title] => Better diagnosis, treatment for HER2 breast cancer
                    [Summary] => 
At a recent medical symposium, pharmaceutical company Roche invited Dr. Anthony Michael Bilous from Australia who talked on “Managing the Patient with Cancer — The Surgeon and Pathologist Working Together.”
                    [DatePublished] => 2012-03-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 695556
                    [Title] => The role of genes in breast cancer
                    [Summary] => 
A female breast represents life. 
                    [DatePublished] => 2011-06-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 678152
                    [Title] => Roche bares positive results of breast cancer drug
                    [Summary] => 
BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.
                    [DatePublished] => 2011-04-21 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 639200
                    [Title] => Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance
                    [Summary] => 
TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women with early-stage HER2-positive breast cancer.
                    [DatePublished] => 2010-12-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 595084
                    [Title] => Roche submits US FDA application for 'T-DM1'
                    [Summary] => 
Roche announced recently that it submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.
                    [DatePublished] => 2010-07-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

HER2

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1305398
                    [Title] => New breast cancer therapy yields better outcomes
                    [Summary] => 
One person is diagnosed with breast cancer somewhere in the world every 22 seconds and more than three people die of breast cancer every five minutes.

                    [DatePublished] => 2014-03-27 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 1243290
                    [Title] => New drug helps people with advanced HER2-positive breast cancer live longer
                    [Summary] => 
Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival), compared to people who received a treatment of their physician’s choice in an open-label phase III study called TH3RESA.

	 

                    [DatePublished] => 2013-10-10 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 791677
                    [Title] => Better diagnosis, treatment for HER2 breast cancer
                    [Summary] => 
At a recent medical symposium, pharmaceutical company Roche invited Dr. Anthony Michael Bilous from Australia who talked on “Managing the Patient with Cancer — The Surgeon and Pathologist Working Together.”
                    [DatePublished] => 2012-03-29 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 695556
                    [Title] => The role of genes in breast cancer
                    [Summary] => 
A female breast represents life. 
                    [DatePublished] => 2011-06-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 678152
                    [Title] => Roche bares positive results of breast cancer drug
                    [Summary] => 
BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.
                    [DatePublished] => 2011-04-21 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 639200
                    [Title] => Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance
                    [Summary] => 
TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women with early-stage HER2-positive breast cancer.
                    [DatePublished] => 2010-12-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [6] => Array
                (
                    [ArticleID] => 595084
                    [Title] => Roche submits US FDA application for 'T-DM1'
                    [Summary] => 
Roche announced recently that it submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.
                    [DatePublished] => 2010-07-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

New breast cancer therapy yields better outcomes

March 27, 2014 - 12:00am

One person is diagnosed with breast cancer somewhere in the world every 22 seconds and more than three people die of breast cancer every five minutes.

Science and Environment

New drug helps people with advanced HER2-positive breast cancer live longer

October 10, 2013 - 12:00am

Roche announced recently that trastuzumab emtansine significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease...

Science and Environment

Better diagnosis, treatment for HER2 breast cancer

March 29, 2012 - 12:00am

At a recent medical symposium, pharmaceutical company Roche invited Dr. Anthony Michael Bilous from Australia who talked on “Managing the Patient with Cancer — The Surgeon and Pathologist Working To...

Science and Environment

The role of genes in breast cancer

June 14, 2011 - 12:00am

A female breast represents life. 

Health And Family

Roche bares positive results of breast cancer drug

April 21, 2011 - 12:00am

BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.

Science and Environment

Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance

December 16, 2010 - 12:00am

TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women...

Science and Environment

Roche submits US FDA application for 'T-DM1'

July 22, 2010 - 12:00am

Roche announced recently that it submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have...

Science and Environment